Applicants: Guy VERGNAULT, et al.

Serial No.: To Be Assigned Filing Date: October 24, 2005 Title: "Tablet with Colored Core"

Page -3-

Docket No.: <u>28069-618-NATL</u>

## **IN THE CLAIMS**

## **Listing of Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

- 1. (Currently amended) A tablet comprising a core-containing active substance and a compression coating surrounding the core, wherein the core contains a colourant colorant or other excipient such that when the tablet is exposed to penetrating radiation the core is contrasted with the coating and is visible through the coating.
- 2. (Currently amended) [A] <u>The</u> tablet according to claim 1 wherein the core contains a <del>colourant</del> colorant that is red iron oxide.
- 3. (Currently amended) [A] <u>The</u> tablet according to claim 1 or claim 2 wherein the core contains an excipient that is opaque to x-rays.
- 4. (Currently amended) [A] <u>The</u> tablet according to claim 3 wherein the excipient is barium sulphate sulfate.
- 5. (Currently amended) [A] The tablet according to any of the preceding claims claim 1 wherein the colourant colorant is present in amounts an amount of 0.1% to about 1.75% by weight based on the total amount weight of the tablet.
- 6. (Currently amended) [A] <u>The</u> tablet according to claim 3-or claim 4 <u>claim 1</u> wherein the excipient is present in amounts an amount of 0.1 to 2% based on the <u>total</u> weight of the tablet.

Express Mail Label No: EV287338015US

Applicants: Guy VERGNAULT, et al.

Serial No.: To Be Assigned Filing Date: October 24, 2005 Title: "Tablet with Colored Core"

Page -4-

7. (Currently amended) [A] <u>The</u> tablet according to <u>any of the preceding claims claim 1</u> wherein the active substance is a glucocorticosteroid selected from prednisone, prednisolone or methylprednisolone.

- 8. (Currently amended) [A] <u>The</u> tablet according to <u>any of the preceding claims claim 1</u> in unit dosage form containing 1 <del>or 5</del> mg prednisone.
- 9. (Currently amended) A method of forming a tablet as defined in any of the preceding elaims the tablet according to claim 1 comprising the step of compressing coating material in granulate powder form around the core.
- 10. (Currently amended) The use of a colouring coloring agent or an excipient opaque to x-ray radiation in the core of a press-coated tablet comprising a core containing an active substance, and a coating surrounding said core, as a means for determining that the core is correctly located within the coating.
- 11. (New) A method of determining whether a core of a press-coated tablet is correctly located within a coating, comprising: preparing a press-coated tablet, said tablet comprising a core containing an active substance and a coating surrounding the core, wherein a coloring agent or an excipient opaque to x-ray radiation is included in the core.
- 12. (New) The tablet according to claim 2 wherein the core contains an excipient that is opaque to x-rays.
- 13. (New) The tablet according to claim 12 wherein the excipient is barium sulfate.
- 14. (New) The tablet according to claim 1 in unit dosage form containing 5 mg prednisone.

Express Mail Label No: EV287338015US

Docket No.: 28069-618-NATL